# US 2021/0330774 A1 · Herv-k-derived antigens as shared tumor antigens for anti-cancer vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330774 A1
- Document ID: US20210330774A1
- Status: Published application
- Kind: A1
- Application number: 17/273,677
- Filed: 2019-09-06
- Published: 2021-10-28
- Earliest claimed: 2018-09-06
- Assignees: Centre Leon Berard; Universite Claude Bernard Lyon 1; Centre National De La Recherche Scientifique; Institut National De La Sante Et De La Recherche Medicale (Inserm)
- Applicants: Centre Leon Berard; Université Claude Bernard Lyon 1; Centre national de la recherche scientifique; Institut National De La Sante Et De La Recherche Medicale (Inserm)
- Inventors: Stéphane DEPIL; Laurie TONON; Christophe CAUX; Paola BONAVENTURA; Jenny VALLADEAU
- Web page: https://patentgrep.com/patent/US20210330774A1

## CPC

- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61K 39/001184: {Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE}
- A61K 39/12: Viral antigens
- A61K 40/42: Cancer antigens
- A61P 31/14: for RNA viruses
- C07K 7/06: having 5 to 11 amino acids
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 2039/572: {cytotoxic response}
- A61K 2039/585: {wherein the target is cancer}
- C12N 2740/10022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/10034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A composition or vaccine comprising at least one peptide, or an expression vector that induces expression of said at least one peptide in vivo, the peptide consisting of, or comprising, shared HERV-K derived antigens, and a pharmaceutically acceptable vehicle or excipient. Composition comprising Cytotoxic T Lymphocytes (CTLs) of a patient treated with such a peptide, or comprising T-cell Receptor (TCR) engineered T cells recognizing such a peptide.

## Claims

### Claim 1

A composition comprising
2, 3, 4, 5, 6 or 7 peptides, or one or more expression vector(s) that induce(s) expression of said 2, 3, 4, 5, 6 or 7 peptides in vivo, the peptides having from 9 to 100 amino acid residues, each one comprising at least one of the epitopes of sequences SEQ ID NO: 1-7, and each peptide comprising at least one different epitope with respect to the others; or
at least one peptide, or an expression vector that induces expression of said at least one peptide in vivo, said peptide having from 9 to 100 amino acids residues and comprising 2, 3, 4, 5, 6 or 7 of the epitopes of sequences SEQ ID NO: 1-7;
and a pharmaceutically acceptable vehicle or excipient.

### Claim 2 (depends on 1)

The composition of claim 1, comprising or expressing one or more peptides comprising the epitopes of sequence SEQ ID NO: 1 and/or 6.

### Claim 3 (depends on 1)

The composition of claim 1, comprising or expressing 3, 4, 5, 6, or the 7 peptides comprising the epitopes of sequences SEQ ID NO: 1 to 7.

### Claim 4 (depends on 1)

The composition of claim 1 wherein the peptides comprise 9 to 100, 70, 50, 40, 30, 25, or 20 amino acid residues and at least one of said epitopes of sequence SEQ ID NO: 1 to 7.

### Claim 5 (depends on 4)

The composition of claim 4, wherein each peptide of 9 to 100, 70, 50, 40, 30, 25, or 20 amino acid residues comprises one specific epitope of SEQ ID NO: 1, 2, 3, 4, 5, 6 or 7.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the peptide(s) comprise(s) 9 to 100, 70, 50, 40, 30, 25, or 20 consecutive amino acid residues of an HERV gag or pol including at least one of said epitopes of sequence SEQ ID NO: 1 to 7.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the peptide(s) comprise(s) 13, 14, 15, 16, 17, or 18, consecutive amino acid residues of an HERV gag or pol including at least one of said epitopes of sequence SEQ ID NO: 1 to 7.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the peptides are selected from the group consisting of SEQ ID NO: 8-14 and the composition comprises 2, 3, 4, 5, 6 or 7 of them.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the peptides consist of 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28 consecutive amino acid residues of sequences SEQ ID NO: 8-14, including the 9-mer epitope, and the composition comprises 2, 3, 4, 5, 6 or 7 of them.

### Claim 10 (depends on 1)

Vaccine or immunogenic composition comprising the composition of claim 1 and a pharmaceutically acceptable vehicle or excipient and preferably an adjuvant.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7)

Composition comprising Cytotoxic T Lymphocytes (CTLs) of a patient treated with a peptide as described in claim 1, or comprising T-cell Receptor (TCR) engineered T cells recognizing a peptide as described in any one of claims 1-7, and a pharmaceutical vehicle.

### Claim 12 (depends on 1)

Composition according to claim 1, for use in treating cancer, in particular breast cancer, including triple negative breast cancer, ovarian cancer, melanoma, sarcoma, teratocarcinoma, bladder cancer, lung cancer (non small cell lung carcinoma and small cell lung carcinoma), head and neck cancer, colo-rectal cancer, glioblastoma and leukemias.

### Claim 13

Isolated peptide selected from the group consisting of the peptides of sequence SEQ ID NO: 2-14, and the peptides having 10 to 100, 70, 50, 40, 30, 25, or 20 amino acids and comprising at least one of said peptides of SEQ ID NO: 2-7.